- Laeyendecker, Oliver;
- Piwowar-Manning, Estelle;
- Fiamma, Agnes;
- Kulich, Michal;
- Donnell, Deborah;
- Bassuk, Deb;
- Mullis, Caroline;
- Chin, Craig;
- Swanson, Priscilla;
- Hackett, John;
- Clarke, William;
- Marzinke, Mark;
- Szekeres, Greg;
- Gray, Glenda;
- Richter, Linda;
- Alexandre, Michel;
- Chariyalertsak, Suwat;
- Chingono, Alfred;
- Celentano, David;
- Sweat, Michael;
- Eshleman, Susan;
- Coates, Thomas;
- Morin, Stephen
BACKGROUND: National Institute of Mental Health Project Accept (HIV Prevention Trials Network [HPTN] 043) is a large, Phase III, community-randomized, HIV prevention trial conducted in 48 matched communities in Africa and Thailand. The study intervention included enhanced community-based voluntary counseling and testing. The primary endpoint was HIV incidence, assessed in a single, cross-sectional, post-intervention survey of >50,000 participants. METHODS: HIV rapid tests were performed in-country. HIV status was confirmed at a central laboratory in the United States. HIV incidence was estimated using a multi-assay algorithm (MAA) that included the BED capture immunoassay, an avidity assay, CD4 cell count, and HIV viral load. RESULTS: Data from Thailand was not used in the endpoint analysis because HIV prevalence was low. Overall, 7,361 HIV infections were identified (4 acute, 3 early, and 7,354 established infections). Samples from established infections were analyzed using the MAA; 467 MAA positive samples were identified; 29 of those samples were excluded because they contained antiretroviral drugs. HIV prevalence was 16.5% (range at study sites: 5.93% to 30.8%). HIV incidence was 1.60% (range at study sites: 0.78% to 3.90%). CONCLUSIONS: In this community-randomized trial, a MAA was used to estimate HIV incidence in a single, cross-sectional post-intervention survey. Results from this analysis were subsequently used to compare HIV incidence in the control and intervention communities. TRIAL REGISTRATION: ClinicalTrials.gov NCT00203749.